Last reviewed · How we verify
Galzin (ZINC ACETATE)
Galzin (ZINC ACETATE) is a small molecule drug developed by ARMOUR PHARM and currently owned by Eton. It was FDA approved in 1980 for various indications including arthropod bite wounds, burn injuries, and hemorrhoids. Galzin is classified as a zinc acetate and is off-patent, meaning it is no longer protected by active patents. It is used to treat conditions related to zinc deficiency or insufficiency. As an off-patent drug, Galzin is available from various manufacturers.
At a glance
| Generic name | ZINC ACETATE |
|---|---|
| Sponsor | Eton |
| Drug class | zinc acetate |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
| First approval | 1980 |
Approved indications
- Arthropod bite wound
- Burn injury
- Diaper rash
- Eruption of skin
- Hemorrhoids
- Hypozincemia
- Itching of ear
- Itching of skin
- Otitis externa
- Proctitis
- Rectal pain
- Skin irritation
- Wilson's disease
- Wound
Common side effects
- Gastric irritation
- Elevations of serum alkaline phosphatase
- Elevations of serum amylase
- Elevations of serum lipase
Serious adverse events
- Pancreatitis
Key clinical trials
- Prospective Pilot Trial to Address Feasibility and Safety of Oral Zinc in GNAO1 Associated Disorders (PHASE2)
- The Effect of Multiple Micronutrient Supplements in Reducing Anemia in Women of Reproductive Age (NA)
- DTPA (Diethylenetriaminepenta-acetate) Chelation for Symptoms After Gadolinium-assisted MRI Exposure (EARLY_PHASE1)
- Efficacy and Safety, Long-term Study of Zinc Acetate to Treat Wilson's Disease in Japan. (PHASE3)
- Healthy Mums, Healthy Babies: Multiple Micronutrient Supplementation in Ethiopia
- Effect of Zinc and Probiotics Supplementation on Laryngeal Cancer Patients Undergoing Laryngectomy Surgery to Improve Prognosis and Better Wound Healing (NA)
- A Comparison of an Investigational Dressing to Tegaderm Matrix Wound Dressing in the Management of Diabetic Foot Ulcers (NA)
- Zn Supplementation in HIV Immunological Non Responders (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Galzin CI brief — competitive landscape report
- Galzin updates RSS · CI watch RSS
- Eton portfolio CI